{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-08",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "67457-991",
      "marketing_end_date": "20270228",
      "generic_name": "trastuzumab",
      "labeler_name": "Mylan Institutional LLC",
      "brand_name": "OGIVRI",
      "active_ingredients": [
        {
          "name": "TRASTUZUMAB",
          "strength": "150 mg/7.4mL"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "67457-991-15",
          "description": "1 VIAL in 1 CARTON (67457-991-15)  / 15 mL in 1 VIAL",
          "marketing_start_date": "20191129",
          "marketing_end_date": "20270228",
          "sample": false
        }
      ],
      "openfda": {},
      "marketing_category": "BLA",
      "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
      "spl_id": "b57e61b9-04b7-4d8b-b7c2-be56a060421b",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "INTRAVENOUS"
      ],
      "marketing_start_date": "20191129",
      "product_id": "67457-991_b57e61b9-04b7-4d8b-b7c2-be56a060421b",
      "application_number": "BLA761074",
      "brand_name_base": "OGIVRI",
      "pharm_class": [
        "HER2/Neu/cerbB2 Antagonists [MoA]",
        "HER2/neu Receptor Antagonist [EPC]"
      ]
    }
  ]
}